Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) shares declined 3.06 percent to close at $23.72 a share Friday. The stock traded between $23.48 and $24.20 on volume of 972,154 shares traded. Analysts at MKM Partners have recently downgraded the company’s rating to "neutral" from "buy". Shares of Auxilium Pharmaceuticals have gained approximately 30.0 percent in the past year.
Find out more about Auxilium Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/AUXL
Heartland Payment Systems, Inc. (NYSE: HPY) shares declined 3.36 percent to close at $43.98 a share Friday. The stock traded between $43.84 and $45.80 on volume of 586,227 shares traded. Analysts at Goldman Sachs have recently upgraded the company’s rating to "neutral" from "buy". Shares of Heartland Payment Systems have gained approximately 40.0 percent in the past year.
Find out more about Heartland Payment Systems including full access to the free equity report at:
www.RDInvesting.com/HPY
Lamar Advertising Co. (NASDAQ: LAMR) shares declined 0.86 percent to close at $49.71 a share Thursday. The stock traded between $49.35 and $50.20 on volume of 1.65 million shares traded. Analysts at Citigroup have recently downgraded the company’s rating to "neutral" from "buy". Shares of Lamar Advertising have gained approximately 17.0 percent in the past year.
Find out more about Lamar Advertising including full access to the free equity report at:
www.RDInvesting.com/LAMR
Sanofi SA (NYSE: SNY) shares declined 3.09 percent to close at $49.22 a share Thursday. The stock traded between $49.01 and $50.24 on volume of 4.48 million shares traded. Analysts at Citigroup have recently downgraded the company’s rating to "neutral" from "buy". Shares of Sanofi have fallen approximately 8.0 percent year-to-date.
Find out more about Sanofi including full access to the free equity report at:
www.RDInvesting.com/SNY
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]